Understanding how specific dietary patterns may enhance or interfere with the mechanisms of Mounjaro and Zepbound is crucial for optimizing outcomes
In a retrospective cohort study including 7,044 patients with T2D, obesity (BMI 27 kg/m 2 ) and HFpEF, combination therapy with an SGLT2i and GLP-1 RA showed a lower risk of HF exacerbation, all-cause emergency department visits and new-onset kidney injury compared with patients only receiving SGLT2i
Chronic viral infections, including Epstein Barr virus, mycoplasma, CMV, or HHV 6 virus can cause Hashimotos disease
Taken once a week through a subcutaneous injection, Zepbound targets GLP-1 and GIP receptors for effective weight loss management
Dr Davin Lim
10.1016/j.theriogenology.2022.08.030 52 SarribleG